- Home
- PTRN vs TARS Comparison
PTRN vs TARS Comparison
Compare PTRN & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTRN | TARS |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PTRN | TARS |
|---|---|---|
| Price | $14.28 | $71.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | $19.89 | ★ $76.56 |
| AVG Volume (30 Days) | ★ 881.5K | 701.3K |
| Earning Date | 11-05-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,293,676,000.00 | $366,100,000.00 |
| Revenue This Year | $39.63 | $147.34 |
| Revenue Next Year | $24.32 | $53.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 67.86 | ★ 182.44 |
| 52 Week Low | $11.21 | $38.51 |
| 52 Week High | $20.10 | $85.25 |
Technical Indicators
Market Signals| Indicator | PTRN | TARS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 28.39 |
| Support Level | N/A | $69.46 |
| Resistance Level | N/A | $76.22 |
| Average True Range (ATR) | 0.00 | 3.15 |
| MACD | 0.00 | -0.98 |
| Stochastic Oscillator | 0.00 | 12.86 |
Price Performance
Historical ComparisonAbout PTRN Pattern Group Inc.
Pattern Group Inc is an ecommerce accelerator, uses its technology platform, data science and a team of experts to drive growth for brands. The Company acquires inventory from brand partners to sell to consumers, enabling full control over content, pricing, logistics and customer service. Brand partners that contract with the Company operate in various industries including health and wellness, beauty and personal care, home and lifestyle, pet, sports and outdoors and consumer electronics.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.